重大事件即時報告 8-K 2026-06-30

Moleculin Biotech 提交8-K：窩輪行使集資約270萬美元，發佈最新投資者簡報

AI 繁中摘要

📄 **申報類型：8-K**  
**公司：Moleculin Biotech, Inc.（代號：MBRX）**  
**報告日期：2026年6月30日**  

---

**重點事件一：發佈投資者簡報**  
公司於2026年6月30日在官方網站上載了最新投資者簡報（作為附件99.1），內容涵蓋企業發展及管線進展。該簡報僅供參考，不視為根據《交易所法》或《證券法》的「申報」文件，亦不納入未來任何申報的參考依據。📊

**重點事件二：後續窩輪行使集資**  
自2026年5月14日提交截至3月31日止季度10-Q報告後，公司共有1,361,500份窩輪獲行使，為公司帶來約270萬美元（USD）的總現金流入。截至2026年6月29日，公司已發行普通股增至7,065,000股。💰

**對投資者的潛在影響**  
- **窩輪行使**：短線增加公司現金儲備，有助支持研發及營運資金；但同時令已發行股數增加，可能對每股盈利帶來攤薄效應。  
- **投資者簡報**：反映管理層積極與市場溝通，投資者可關注簡報中提及的臨床進度及合作機會。  
- 整體而言，本次8-K顯示公司成功利用窩輪工具集資，股份發行量適度擴大，資金壓力略有緩解，但需留意未來稀釋風險。📈

展開英文正文

mbrx20260629_8k.htm
 
 
 

false
0001659617

0001659617

2026-06-30
2026-06-30

  

 UNITED STATES
 

 SECURITIES AND EXCHANGE COMMISSION
 

 WASHINGTON, D.C. 20549
 

  

 FORM 8-K
 

  

 CURRENT REPORT
 

  

 PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 

  

 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 30, 2026
 

  

 
 
 

  

  

 MOLECULIN BIOTECH, INC.
 

 (Exact Name of Registrant as Specified in its Charter)

  

 
 Delaware
001-37758
47-4671997

 

 (State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)

 

 
  

 5300 Memorial Drive, Suite 950, Houston, TX 77007
 

 (Address of principal executive offices and zip code)

  

 (713) 300-5160
 

 (Registrant’s telephone number, including area code)

 (Former name or former address, if changed from last report)

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  

 
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 
 
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 
 
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 
 
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

 

 
  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐
 

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

 Securities registered pursuant to Section 12(b) of the Act:

  

 
 Title of each class
Trading Symbol (s)
Name of each exchange on which registered

 

 Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC

 

 
  

 
 
 

 

 
 

 

  

 
 Item 7.01
Regulation FD Disclosure

 

 
  

 On June 30, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

  

 The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

  

 
 Item 8.01
Other Events

 

  
Subsequent to the filing on May 14, 2026 of the Company's Form 10-Q for the period ended March 31, 2026, warrants to purchase 1,361,500 shares of Company common stock have been exercised for gross proceeds of approximately $2.7 million. As of June 29, 2026, the Company had 7,065,000 shares of common stock outstanding.
 

 

 Item 9.01
Financial Statements and Exhibits.

 

 
  

 
 (d)
Exhibits.

 

 
  

 
 Exhibit No.
Description

 

 
  

 
 99.1
Investor Presentation dated June 2026

 

 
  

 
 104
Cover page Interactive Data File (formatted as Inline XBRL document)

 

 
  

 SIGNATURE
 

  

 Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

 
  
MOLECULIN BIOTECH, INC. 
 

 

  
 
 
 

 

  
 
 
 

 

  
Date:
June 30, 2026
 

 

  
 
 
 

 

  
By:
/s/ Jonathan P. Foster
 

 

  
 
Jonathan P. Foster